137 related articles for article (PubMed ID: 29242304)
21. Benefit of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia.
Schiller G; Gajewski J; Lee M; Ho W; Territo M; Champlin R
Leuk Lymphoma; 1994 Sep; 15(1-2):85-90. PubMed ID: 7858506
[TBL] [Abstract][Full Text] [Related]
22. Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
Halpern AB; Othus M; Huebner EM; Buckley SA; Pogosova-Agadjanyan EL; Orlowski KF; Scott BL; Becker PS; Hendrie PC; Chen TL; Percival MM; Estey EH; Stirewalt DL; Walter RB
Leukemia; 2017 Dec; 31(12):2560-2567. PubMed ID: 28555084
[TBL] [Abstract][Full Text] [Related]
23. Liposomal Cytarabine-Daunorubicin (CPX-351) Extravasation: Case Report and Literature Review.
Howell G; Oliai C; Schiller G
Anticancer Res; 2018 Dec; 38(12):6927-6930. PubMed ID: 30504411
[TBL] [Abstract][Full Text] [Related]
24. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420.
Lee EJ; George SL; Caligiuri M; Szatrowski TP; Powell BL; Lemke S; Dodge RK; Smith R; Baer M; Schiffer CA
J Clin Oncol; 1999 Sep; 17(9):2831-9. PubMed ID: 10561359
[TBL] [Abstract][Full Text] [Related]
25. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
26. Double intensive consolidation chemotherapy in adult acute myeloid leukemia.
Harousseau JL; Milpied N; Briere J; Desablens B; Leprise PY; Ifrah N; Gandhour B; Casassus P
Semin Hematol; 1991 Jul; 28(3 Suppl 4):80-3. PubMed ID: 1780758
[No Abstract] [Full Text] [Related]
27. [Treatment of acute myeloid leukemia in adults with a combination of daunomycin and cytosine-arabinoside].
Brincker H
Ugeskr Laeger; 1972 Oct; 134(42):2195-200. PubMed ID: 4563112
[No Abstract] [Full Text] [Related]
28. Daunorubicin-prednisone remission induction with hydroxyurea maintenance in acute non-lymphocytic leukemia.
Bloomfield CD; Brunning RD; Theologides A; Kennedy BJ
Cancer; 1973 Apr; 31(4):931-8. PubMed ID: 4513295
[No Abstract] [Full Text] [Related]
29. [Analysis on clinical response of IA and DA regimens in the treatment of 74 newly diagnosed acute myeloid leukemia patients].
Li XY; Wang X; Li Y
Zhonghua Xue Ye Xue Za Zhi; 2013 Jan; 34(1):67-8. PubMed ID: 23597470
[No Abstract] [Full Text] [Related]
30. Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment.
Champlin R; Gajewski J; Nimer S; Vollset S; Landaw E; Winston D; Schiller G; Ho W
J Clin Oncol; 1990 Jul; 8(7):1199-206. PubMed ID: 1694236
[TBL] [Abstract][Full Text] [Related]
31. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.
Schaich M; Parmentier S; Kramer M; Illmer T; Stölzel F; Röllig C; Thiede C; Hänel M; Schäfer-Eckart K; Aulitzky W; Einsele H; Ho AD; Serve H; Berdel WE; Mayer J; Schmitz N; Krause SW; Neubauer A; Baldus CD; Schetelig J; Bornhäuser M; Ehninger G
J Clin Oncol; 2013 Jun; 31(17):2094-102. PubMed ID: 23630210
[TBL] [Abstract][Full Text] [Related]
32. Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.
Stone RM; Mazzola E; Neuberg D; Allen SL; Pigneux A; Stuart RK; Wetzler M; Rizzieri D; Erba HP; Damon L; Jang JH; Tallman MS; Warzocha K; Masszi T; Sekeres MA; Egyed M; Horst HA; Selleslag D; Solomon SR; Venugopal P; Lundberg AS; Powell B
J Clin Oncol; 2015 Apr; 33(11):1252-7. PubMed ID: 25732165
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of acute myeloblastic leukemia with daunorubicin and cytosine-arabinoside].
Thorling K; Petersen HS; Jensen KB; Bastrup-Madsen P
Ugeskr Laeger; 1972 Oct; 134(42):2201-5. PubMed ID: 4507751
[No Abstract] [Full Text] [Related]
34. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.
Kolitz JE; George SL; Dodge RK; Hurd DD; Powell BL; Allen SL; Velez-Garcia E; Moore JO; Shea TC; Hoke E; Caligiuri MA; Vardiman JW; Bloomfield CD; Larson RA;
J Clin Oncol; 2004 Nov; 22(21):4290-301. PubMed ID: 15514371
[TBL] [Abstract][Full Text] [Related]
35. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.
Holowiecki J; Grosicki S; Giebel S; Robak T; Kyrcz-Krzemien S; Kuliczkowski K; Skotnicki AB; Hellmann A; Sulek K; Dmoszynska A; Kloczko J; Jedrzejczak WW; Zdziarska B; Warzocha K; Zawilska K; Komarnicki M; Kielbinski M; Piatkowska-Jakubas B; Wierzbowska A; Wach M; Haus O
J Clin Oncol; 2012 Jul; 30(20):2441-8. PubMed ID: 22508825
[TBL] [Abstract][Full Text] [Related]
36. Dose-intensive treatment of acute myelogenous leukemia: improved survival?
Schiller G
J Clin Oncol; 1995 Jul; 13(7):1828-30. PubMed ID: 7602375
[No Abstract] [Full Text] [Related]
37. A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia.
Wiernik PH; Case DC; Periman PO; Arlin ZA; Weitberg AB; Ritch PS; Todd MB
Semin Oncol; 1989 Feb; 16(1 Suppl 2):25-9. PubMed ID: 2928807
[No Abstract] [Full Text] [Related]
38. Priming with granulocyte colony-stimulating factor--relation to high-dose cytarabine in acute myeloid leukemia.
Büchner T; Berdel WE; Hiddemann W
N Engl J Med; 2004 May; 350(21):2215-6. PubMed ID: 15152074
[No Abstract] [Full Text] [Related]
39. Going beyond 7 + 3 regimens in the treatment of adult acute myeloid leukemia.
Tefferi A; Letendre L
J Clin Oncol; 2012 Jul; 30(20):2425-8. PubMed ID: 22529263
[No Abstract] [Full Text] [Related]
40. [Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia].
Malpas J; Mathé G; Hayat M
Bull Cancer; 1974; 61(3):411-8. PubMed ID: 4533741
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]